* Alimera Sciences Inc ALIM.OQ ALIM.O is expected
to show a
rise in quarterly revenue when it reports results
* The Alpharetta Georgia-based company is expected to
report a
67.1% increase in revenue to $22.717 million from $13.6 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Alimera Sciences
Inc is
for a loss of 6 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Alimera
Sciences
Inc is $8, above its last closing price of $3.11.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.00 0.02 -1.32 Missed -8,900
Mar. 31 2023 -0.51 -0.32 -0.71 Missed -121.9
Dec. 31 2022 -0.33 -0.54 Missed -61.2
Sep. 30 2022 -0.40 -0.40 -0.75 Missed -86
Jun. -0.55 -0.55 -0.45 Beat 18.7
30 2022
Mar. 31 2022 -0.69 -0.69 -0.85 Missed -23.2
Dec. 31 2021 -0.41 -0.42 -0.59 Missed -40.5
Sep. 30 2021 -0.52 -0.52 -0.60 Missed -14.3
This summary was machine generated October 24 at 17:05 GMT. All
figures in US dollars unless otherwise stated